Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.52 |
| ▸ | CNR2 | P34972 | 3/20 | 0.52 |
| ▸ | NAMPT | P43490 | 8/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26898605 | 0.85 | CNR2 (0.49) | CNR1CNR2NAMPTCYP2C9ADORA2B | |
| SCHEMBL27021658 | 0.85 | CNR2 (0.49) | CNR1CNR2NAMPTCYP2C9ADORA2B | |
| SCHEMBL4253583 | 0.81 | CNR1 (0.60) | CNR1CNR2NAMPTCYP2C9GRM4 | |
| SCHEMBL13161996 | 0.80 | NAMPT (0.50) | NAMPTGABRA5 | |
| SCHEMBL26856708 | 0.79 | MAPT (0.66) | — | |
| SCHEMBL28503120 | 0.78 | P2RX7 (0.47) | CNR2NAMPT | |
| SCHEMBL5422989 | 0.77 | NAMPT (0.59) | NAMPTGABRA5 | |
| SCHEMBL13162011 | 0.76 | NAMPT (0.52) | CNR2NAMPTADORA2BGABRA5 | |
| SCHEMBL13161990 | 0.76 | GRM5 (0.54) | GRM4 | |
| SCHEMBL26856716 | 0.74 | CNR2 (0.43) | CNR1CNR2CYP2C9ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |